Topic: Brilinta
LONDON (Reuters) - AstraZeneca Plc has no plans to run a clinical trial to confirm the reasons behind a discrepancy between the performance of its newly approved heart drug Brilinta in North America and other parts of the world.Some analysts have speculated ...
LONDON (Reuters) - AstraZeneca's revenue fell 4 percent in the third quarter, hit by generic competition to key drugs -- particularly in the United States -- and the absence of last year's windfall sales of swine flu vaccine.AstraZeneca is moving into a ...
Sell-side analyst price targets for AstraZeneca (AZN) are up, despite concerns over upcoming patent expiration and less-than-ideal results from experimental cancer drug trials. Shore Capital's Brian White kept his Buy recommendation despite news that Astra's experimental prostate cancer pill zibotentan had failed ...
LONDON (Reuters) - AstraZeneca's experimental prostate cancer pill zibotentan failed to improve survival in a late-stage clinical trial, dealing a fresh blow to the company's oncology pipeline.As a result, AstraZeneca plans no regulatory submissions for zibotentan at this time and a spokesman ...
AstraZeneca today announced that the US Food and Drug Administration (FDA) has extended the time to complete its review of the New Drug Application (NDA) for ticagrelor (Brilinta).. AstraZeneca will continue to work closely with the FDA to support the review of ...
STOCKHOLM (Reuters) - AstraZeneca's new blood-thinning drug Brilinta has been given a class 1 recommendation as a treatment option under European medical guidelines, even though it has yet to be approved for sale.New European Society of Cardiology guidelines include the medicine, which ...
LONDON -- AstraZeneca PLC doubled its share buyback program on Thursday after posting strong second quarter results and revealing that a key new drug -- its blood thinner Brilinta -- has been given a thumbs up by an advisory committee of the ...
ADELPHI, Maryland (Reuters) - AstraZeneca Plc's experimental blood thinner goes before U.S. advisers on Wednesday, facing questions over why a trial of the potential blockbuster drug failed to cut heart attacks and deaths in North American patients.Brilinta, with expected annual sales of ...
AstraZeneca PLC said Thursday it has applied to U.S. regulators to market its blood clot preventer Brilinta, a potential new big seller for the company.AstraZeneca submitted a new drug application to the U.S. Food and Drug Administration for Brilinta, also known as ...
LONDON-AstraZeneca PLC said Thursday it has applied to U.S. regulators to market its blood clot preventer Brilinta, a potential new big seller for the company.. AstraZeneca submitted a new drug application to the U.S. Food and Drug Administration for Brilinta, also known ...
